Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zarnestra in Superficial Transitional Cell Carcinoma of Bladder
NCT00047216Phase 2Completed
- Sponsor
- University Health Network
- Start
- Nov 2002
- Primary completion
- Mar 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of tipifarnib in bladder cancer, sponsored by University Health Network. Primary endpoint: 1-year recurrence-free survival rate. Started Nov 2002; status: completed.
02
Drugs
tipifarnib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT00047216.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00047216.